Patents by Inventor Takafumi Harada
Takafumi Harada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250034071Abstract: Compounds and use of the compounds for formula (I) where X is selected from the group consisting of a single bond, O, N—(C1-C4)-alkyl, N—Ar1, CR5R6, S, S(O) and SO2; Z1 and Z2 are independently selected from hydrogen, -Alk-OH, —CH2—Ar2—CH2—OH, -Alk?-C(O)ORx, —CH2—Ar2—C(O)ORx and —C(O)—Ar2—C(O)ORx, where Rx is selected from the group consisting of hydrogen, phenyl, benzyl and C1-C4-alkyl; R1 and R2 are independently selected from the group consisting of optionally substituted mono- or polycyclic aryl having from 6 to 26 carbon atoms as ring members and optionally substituted mono- or polycyclic hetaryl having a total of 5 to 26 atoms as ring members, R5 is selected from the group consisting of hydrogen, C1-C4-alkyl and a radical Ar1; R6 is selected from the group consisting of hydrogen and C1-C4-alkyl; Alk is C2-C4-alkandiyl; provided that R1 and R2 are not both phenyl, if R3 and R4 are both hydrogen.Type: ApplicationFiled: September 8, 2022Publication date: January 30, 2025Applicant: MITSUBISHI GAS CHEMICAL COMPANY, INC.Inventors: Noriyuki KATO, Katsushi NISHIMORI, Atsushi MOTEGI, Kentaro ISHIHARA, Shinya IKEDA, Takafumi WATANABE, Tatsunobu OGATA, Kazutaka TAKAMATSU, Yutaro HARADA, Vasyl ANDRUSHKO, Karl REUTER, Philipp KOSCHKER, Florian STOLZ, Mark KANTOR
-
Publication number: 20250019332Abstract: The present invention relates to compounds of the formula (I) where X is selected from the group consisting of a single bond, O, N—(C1-C4)-alkyl, N—Ar1, CR5R6, S, S(O) and SO2; Z1 and Z2 are independently selected from hydrogen, -Alk-OH, —CH2—Ar2—CH2—OH, -Alk?-C(O)ORx, —CH2—Ar2—C(O)ORx and —C(O)—Ar2—C(O)ORx, where Rx is selected from the group consisting of hydrogen, phenyl, benzyl and C1-C4-alkyl; R1 and R2 are independently selected from the group consisting of optionally substituted mono- or polycyclic aryl having from 6 to 26 carbon atoms as ring members and optionally substituted mono- or polycyclic hetaryl having a total of 5 to 26 atoms as ring members, R5 is selected from the group consisting of hydrogen, C1-C4-alkyl and a radical Ar1; R6 is selected from the group consisting of hydrogen and C1-C4-alkyl; Alk is C2-C4-alkandiyl; provided that R1 and R2 are not both phenyl, if R3 and R4 are both hydrogen.Type: ApplicationFiled: September 8, 2022Publication date: January 16, 2025Inventors: Vasyl ANDRUSHKO, Karl REUTER, Philipp KOSCHKER, Florian STOLZ, Mark KANTOR, Noriyuki KATO, Katsushi NISHIMORI, Atsushi MOTEGI, Kentaro ISHIHARA, Shinya IKEDA, Takafumi WATANABE, Tatsunobu OGATA, Kazutaka TAKAMATSU, Yutaro HARADA
-
Patent number: 11870792Abstract: An abnormal traffic analysis apparatus includes receiving means for receiving traffic from a device via any of a plurality of communication paths in which different communication methods are used, multiple communication management means for identifying a communication path through which the traffic is transmitted, analysis method determination means for determining an analysis algorithm for detecting abnormality of the traffic according to the communication path identified by the multiple communication management means, analysis means for analyzing whether or not the traffic is abnormal traffic by using the analysis algorithm determined by the analysis method determination means, and analysis result recording means for recording a result of analysis performed by the analysis means.Type: GrantFiled: March 8, 2019Date of Patent: January 9, 2024Assignee: NIPPON TELEGRAPH AND TELEPHONE CORPORATIONInventors: Takafumi Harada, Gembu Morohashi, Hiroki Ito
-
Patent number: 11553347Abstract: An abnormal traffic analysis apparatus includes receiving means for receiving traffic from a device, analysis means for analyzing whether or not traffic received from the device is abnormal traffic, analysis result recording means for recording a result of analysis performed by the analysis means, and device management means for managing movement of the device between edges. If it is determined by the device management means that a device that is a target of analysis performed by the analysis means moves to an edge, the receiving means creates information for continuing analysis of traffic received from the device and transmits the information to an apparatus for analyzing traffic that is included in the edge to which the device moves.Type: GrantFiled: March 8, 2019Date of Patent: January 10, 2023Assignee: NIPPON TELEGRAPH AND TELEPHONE CORPORATIONInventors: Takafumi Harada, Gembu Morohashi, Hiroki Ito
-
Publication number: 20220301422Abstract: An anomaly detection system includes a memory and a processor configured to divide a set of data measured in a geographical space into a plurality of groups that represent a plurality of predetermined geographical subspaces, calculate, for each group, a feature amount in the group using data included in the group, and determine whether or not there is a group that is likely to include abnormal data, among the plurality of groups, using the feature amount in each of the plurality of groups.Type: ApplicationFiled: September 12, 2019Publication date: September 22, 2022Applicant: NIPPON TELEGRAPH AND TELEPHONE CORPORATIONInventors: Takafumi HARADA, Keita HASEGAWA, Tomoaki WASHIO, Yoshihito OSHIMA
-
Publication number: 20220253677Abstract: An action learning system includes a memory, and a processor configured to train, based on first data indicating a property of an environment in which data is collected from multiple devices and to which an action determined by a first neural network according to a state of the environment is applied and second data indicating a property of the environment to which the action is not applied, a second neural network that calculates a similarity degree between distributions of the first data and the second data, and train, after the second neural network is trained, the first neural network that determines an action according to the state of the environment, by reinforcement learning including, in a reward, a value that changes based on a relationship between a similarity degree and a parameter set by a user, the similarity degree being calculated by the second neural network based.Type: ApplicationFiled: July 10, 2019Publication date: August 11, 2022Applicant: NIPPON TELEGRAPH AND TELEPHONE CORPORATIONInventors: Yuichiro DAN, Keita HASEGAWA, Takafumi HARADA, Tomoaki WASHIO, Yoshihito OSHIMA
-
Patent number: 11117187Abstract: Disclosed is a casting nozzle intended to suppress or prevent breaking of a nozzle body thereof. The casting nozzle comprises: a nozzle body; a metal casing disposed to surround an upper end of the nozzle body to form a gas pool between an outer peripheral surface of the upper end of the nozzle body and an inner peripheral surface of the metal casing; and a bridging segment provided in at least a part of the gas pool to bridge between the outer peripheral surface of the upper end of the nozzle body and the inner peripheral surface of the metal casing.Type: GrantFiled: June 19, 2018Date of Patent: September 14, 2021Assignee: KROSAKIHARIMA CORPORATIONInventors: Takafumi Harada, Kouichi Tachikawa
-
Publication number: 20210058794Abstract: An abnormal traffic analysis apparatus includes receiving means for receiving traffic from a device, analysis means for analyzing whether or not traffic received from the device is abnormal traffic, analysis result recording means for recording a result of analysis performed by the analysis means, and device management means for managing movement of the device between edges. If it is determined by the device management means that a device that is a target of analysis performed by the analysis means moves to an edge, the receiving means creates information for continuing analysis of traffic received from the device and transmits the information to an apparatus for analyzing traffic that is included in the edge to which the device moves.Type: ApplicationFiled: March 8, 2019Publication date: February 25, 2021Applicant: NIPPON TELEGRAPH AND TELEPHONE CORPORATIONInventors: Takafumi HARADA, Gembu MOROHASHI, Hiroki ITO
-
Publication number: 20210029149Abstract: An abnormal traffic analysis apparatus includes receiving means for receiving traffic from a device via any of a plurality of communication paths in which different communication methods are used, multiple communication management means for identifying a communication path through which the traffic is transmitted, analysis method determination means for determining an analysis algorithm for detecting abnormality of the traffic according to the communication path identified by the multiple communication management means, analysis means for analyzing whether or not the traffic is abnormal traffic by using the analysis algorithm determined by the analysis method determination means, and analysis result recording means for recording a result of analysis performed by the analysis means.Type: ApplicationFiled: March 8, 2019Publication date: January 28, 2021Applicant: NIPPON TELEGRAPH AND TELEPHONE CORPORATIONInventors: Takafumi HARADA, Gembu MOROHASHI, Hiroki ITO
-
Patent number: 10806753Abstract: A core-shell gel particle of the invention contains a crosslinked hyaluronic acid, has a higher equilibrium swelling capacity at the surface than at the center, the equilibrium swelling capacity showing a change curve with an inflection point from the center to the surface, and has a probe pushing force of 20 nN or less from the surface to a depth of 800 nm.Type: GrantFiled: July 31, 2018Date of Patent: October 20, 2020Assignee: Denka Company LimitedInventors: Akio Ohno, Masamichi Hashimoto, Harei Nemoto, Takafumi Harada, Kenji Fujii
-
Publication number: 20200108440Abstract: Disclosed is a casting nozzle intended to suppress or prevent breaking of a nozzle body thereof. The casting nozzle comprises: a nozzle body; a metal casing disposed to surround an upper end of the nozzle body to form a gas pool between an outer peripheral surface of the upper end of the nozzle body and an inner peripheral surface of the metal casing; and a bridging segment provided in at least a part of the gas pool to bridge between the outer peripheral surface of the upper end of the nozzle body and the inner peripheral surface of the metal casing.Type: ApplicationFiled: June 19, 2018Publication date: April 9, 2020Applicant: KROSAKIHARIMA CORPORATIONInventors: Takafumi HARADA, Kouichi TACHIKAWA
-
Patent number: 10449212Abstract: Provided is an immunostimulating oligonucleotide that is suitable for industrial production and has an excellent type-I IFN inducing activity even when not modified to become a phosphorothioate. This linear double-stranded oligonucleotide contains 10-100 base pairs, wherein the single-stranded oligonucleotides constituting the double-stranded oligonucleotide each contain 2-20 phosphodiester-mediated cytosine-guanine (CpG) sequences, and at least 90% of the internucleotide bonds in each single-stranded oligonucleotide are phosphodiester bonds.Type: GrantFiled: July 8, 2016Date of Patent: October 22, 2019Assignees: NATIONAL INSTITUTE FOR MATERIALS SCIENCE, DENKA COMPANY LIMITEDInventors: Nobutaka Hanagata, Hiroshi Otsuka, Takafumi Harada
-
Patent number: 10421760Abstract: Provided are a novel compound or a salt thereof, and a pharmaceutical composition comprising the same, which selectively and strongly inhibit JAK3, exhibit an excellent activity for suppressing the growth of human peripheral blood monocytes and an excellent oral absorbability, and exhibits an activity of inhibiting IL-2-induced IFN-? production in vivo. A compound represented by formula (I) [wherein X represents —CH?CH—, —NH—, a sulfur atom or an oxygen atom; and n represents an integer of 0 to 2], or a salt thereof.Type: GrantFiled: July 29, 2016Date of Patent: September 24, 2019Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Masayuki Nakamura, Hiroyoshi Yamanaka, Morihiro Mitsuya, Takafumi Harada
-
Publication number: 20180333430Abstract: A core-shell gel particle of the invention contains a crosslinked hyaluronic acid, has a higher equilibrium swelling capacity at the surface than at the center, the equilibrium swelling capacity showing a change curve with an inflection point from the center to the surface, and has a probe pushing force of 20 nN or less from the surface to a depth of 800 nm.Type: ApplicationFiled: July 31, 2018Publication date: November 22, 2018Applicant: DENKA COMPANY LIMITEDInventors: Akio OHNO, Masamichi HASHIMOTO, Harei NEMOTO, Takafumi HARADA, Kenji FUJII
-
Publication number: 20180208598Abstract: Provided are a novel compound or a salt thereof, and a pharmaceutical composition comprising the same, which selectively and strongly inhibit JAK3, exhibit an excellent activity for suppressing the growth of human peripheral blood monocytes and an excellent oral absorbability, and exhibits an activity of inhibiting IL-2-induced IFN-? production in vivo. A compound represented by formula (I) [wherein X represents —CH?CH—, —NH—, a sulfur atom or an oxygen atom; and n represents an integer of 0 to 2], or a salt thereof.Type: ApplicationFiled: July 29, 2016Publication date: July 26, 2018Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Masayuki NAKAMURA, Hiroyoshi YAMANAKA, Morihiro MITSUYA, Takafumi HARADA
-
Publication number: 20180193371Abstract: Provided is an immunostimulating oligonucleotide that is suitable for industrial production and has an excellent type-I IFN inducing activity even when not modified to become a phosphorothioate. This linear double-stranded oligonucleotide contains 10-100 base pairs, wherein the single-stranded oligonucleotides constituting the double-stranded oligonucleotide each contain 2-20 phosphodiester-mediated cytosine-guanine (CpG) sequences, and at least 90% of the internucleotide bonds in each single-stranded oligonucleotide are phosphodiester bonds.Type: ApplicationFiled: July 8, 2016Publication date: July 12, 2018Inventors: Nobutaka HANAGATA, Hiroshi OTSUKA, Takafumi HARADA
-
Patent number: 9782392Abstract: A method for treating rheumatoid arthritis, multiple sclerosis, or a disease involving JAK3, including administering a compound of the formula (I) or a salt thereof to a subjectType: GrantFiled: January 12, 2017Date of Patent: October 10, 2017Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Masayuki Nakamura, Hiroyoshi Yamanaka, Kazuaki Shibata, Morihiro Mitsuya, Takafumi Harada
-
Patent number: 9676773Abstract: Provided is a novel compound having a selective JAK3-inhibitory effect and also having excellent oral absorbability. Also provided is a pharmaceutical agent, which is based on a JAK3-inhibitory effect and is useful for preventing and/or treating a disease involving the JAK3, and in particular, rheumatoid arthritis or multiple sclerosis. An azaindole derivative having a cycloalkenyl group, which is represented by the following formula (I), or a salt thereof, and a pharmaceutical composition containing the same: where R1 to R4, m and n have the same meanings as those defined in the description.Type: GrantFiled: February 4, 2015Date of Patent: June 13, 2017Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Masayuki Nakamura, Hiroyoshi Yamanaka, Kazuaki Shibata, Morihiro Mitsuya, Takafumi Harada
-
Publication number: 20170119743Abstract: A method for treating rheumatoid arthritis, multiple sclerosis, or a disease involving JAK3, including administering a compound of the formula (I) or a salt thereof to a subjectType: ApplicationFiled: January 12, 2017Publication date: May 4, 2017Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Masayuki NAKAMURA, Hiroyoshi YAMANAKA, Kazuaki SHIBATA, Morihiro MITSUYA, Takafumi HARADA
-
Publication number: 20160340353Abstract: Provided is a novel compound having a selective JAK3-inhibitory effect and also having excellent oral absorbability. Also provided is a pharmaceutical agent, which is based on a JAK3-inhibitory effect and is useful for preventing and/or treating a disease involving the JAK3, and in particular, rheumatoid arthritis or multiple sclerosis. An azaindole derivative having a cycloalkenyl group, which is represented by the following formula (I), or a salt thereof, and a pharmaceutical composition containing the same: where R1 to R4, m and n have the same meanings as those defined in the description.Type: ApplicationFiled: February 4, 2015Publication date: November 24, 2016Applicant: TAIHO PHARMARCEUTICAL CO., LTD.Inventors: Masayuki NAKAMURA, Hiroyoshi YAMANAKA, Kazuaki SHIBATA, Morihiro MITSUYA, Takafumi HARADA